Evidence map›Paper›PMID 35460473›Full record

ReviewCurrent cardiology reports2022

Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease.

Ghadeer K Dawwas, Geoffrey D Barnes

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ghadeer K DawwasCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. gkdawwas@pennmedicine.upenn.edu.ORCID 0000-0002-7982-7419
Geoffrey D BarnesDivision of Cardiovascular Medicine, Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan Health System, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd, Building #14, Room G214, Ann Arbor, MI, 48109, USA.
University of Michigan · USUniversity of Pennsylvania · US

Funding

Anticoagulant use, safety, and effectiveness for venous thromboembolism prevention in inflammatory bowel disease patientsK99HL159230 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI DAWWAS, GHADEER K. · 2021 to 2022
$184k
NHLBI NIH HHS K99 HL159230
6 · The paper itself

Abstract

purpose of reviewDirect oral anticoagulants (DOACs) are increasingly used for the treatment and prevention of thromboembolic events in patients with non-valvular atrial fibrillation (AF). Evidence regarding their role in patients with AF and concurrent valvular heart disease (VHD) continues to evolve. RECENT

findingsPost hoc analyses of randomized clinical trials suggest that DOACs are non-inferior to warfarin for the prevention of stroke or systemic embolism in patients with AF and VHD. Emerging evidence from observational data showed a favorable benefit-risk profile for DOACs compared to warfarin in patients with AF and VHD. DOACs are an attractive option for the treatment of patients with AF and VHD who cannot tolerate or have contraindications to warfarin therapy. Future studies are needed to evaluate their effectiveness, safety, and examine variability in the direction and magnitude of treatment effects in selected VHD subgroups.

Indexed as

Atrial FibrillationHeart Valve DiseasesStrokeAdministration, OralAnticoagulantsHumansWarfarinAnticoagulantsWarfarinAnticoagulantsAtrial fibrillationDOACsStrokeValvular heart diseaseWarfarin

Identifiers

PMID35460473
PMCPMC10877551
OpenAlexW4224318753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.